Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG Block for Cold Induced Headache
NCT06310200Phase 1Active, not recruiting
- Sponsor
- Wright State University
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of lidocaine 10% oropharyngeal spray in cold-stimulus headache (CSH) (2 arms), sponsored by Wright State University. Primary endpoint: Does sphenopalatine ganglion (SPG) block prevent cold induced cephalgia at 5 months. Started Jan 2025; status: active, not recruiting.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
cold-stimulus headache (CSH)
Beyond the preview
Go deeper on NCT06310200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310200.